These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

183 related articles for article (PubMed ID: 10762139)

  • 21. Striatal dysfunction increases basal ganglia output during motor cortex activation in parkinsonian rats.
    Belluscio MA; Riquelme LA; Murer MG
    Eur J Neurosci; 2007 May; 25(9):2791-804. PubMed ID: 17561844
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease.
    Obeso JA; Rodríguez-Oroz MC; Benitez-Temino B; Blesa FJ; Guridi J; Marin C; Rodriguez M
    Mov Disord; 2008; 23 Suppl 3():S548-59. PubMed ID: 18781672
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Levodopa therapy: consequences of the nonphysiologic replacement of dopamine.
    Chase TN
    Neurology; 1998 May; 50(5 Suppl 5):S17-25. PubMed ID: 9591518
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Drug insight: Continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Olanow CW; Obeso JA; Stocchi F
    Nat Clin Pract Neurol; 2006 Jul; 2(7):382-92. PubMed ID: 16932589
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical features, diagnosis, and imaging of parkinsonian syndromes.
    Poewe W
    Curr Opin Neurol Neurosurg; 1993 Jun; 6(3):333-8. PubMed ID: 8507902
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Altered D(1) dopamine receptor trafficking in parkinsonian and dyskinetic non-human primates.
    Guigoni C; Doudnikoff E; Li Q; Bloch B; Bezard E
    Neurobiol Dis; 2007 May; 26(2):452-63. PubMed ID: 17350277
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cyclic AMP responsive element binding protein phosphorylation and persistent expression of levodopa-induced response alterations in unilateral nigrostriatal 6-OHDA lesioned rats.
    Oh JD; Chartisathian K; Ahmed SM; Chase TN
    J Neurosci Res; 2003 Jun; 72(6):768-80. PubMed ID: 12774317
    [TBL] [Abstract][Full Text] [Related]  

  • 28. L-Dopa treatment abolishes the numerical increase in striatal dopaminergic neurons in parkinsonian monkeys.
    Huot P; Lévesque M; Morissette M; Calon F; Dridi M; Di Paolo T; Parent A
    J Chem Neuroanat; 2008 Jan; 35(1):77-84. PubMed ID: 17706922
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Rationale for and use of NMDA receptor antagonists in Parkinson's disease.
    Hallett PJ; Standaert DG
    Pharmacol Ther; 2004 May; 102(2):155-74. PubMed ID: 15163596
    [TBL] [Abstract][Full Text] [Related]  

  • 30. l-DOPA dosage is critically involved in dyskinesia via loss of synaptic depotentiation.
    Picconi B; Paillé V; Ghiglieri V; Bagetta V; Barone I; Lindgren HS; Bernardi G; Angela Cenci M; Calabresi P
    Neurobiol Dis; 2008 Feb; 29(2):327-35. PubMed ID: 17997101
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Striatal dopaminoceptive system changes and motor response complications in L-dopa-treated patients with advanced Parkinson's disease.
    Chase TN; Engber TM; Mouradian MM
    Adv Neurol; 1993; 60():181-5. PubMed ID: 8420133
    [No Abstract]   [Full Text] [Related]  

  • 32. Alterations in nigral NMDA and GABAA receptor control of the striatal dopamine level after repetitive exposures to nitrogen narcosis.
    Lavoute C; Weiss M; Rostain JC
    Exp Neurol; 2008 Jul; 212(1):63-70. PubMed ID: 18452916
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Automimmune response to dopamine-receptor as a possible mechanism in the pathogenesis of Parkinson's disease and schizophrenia.
    Abramsky O; Litvin Y
    Perspect Biol Med; 1978; 22(1):104-14. PubMed ID: 733451
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Medicinal treatment of idiopathic Parkinson's disease].
    Klockgether T
    Nervenarzt; 2003 Mar; 74 Suppl 1():S12-21. PubMed ID: 12624679
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The NR2B-selective NMDA receptor antagonist CP-101,606 exacerbates L-DOPA-induced dyskinesia and provides mild potentiation of anti-parkinsonian effects of L-DOPA in the MPTP-lesioned marmoset model of Parkinson's disease.
    Nash JE; Ravenscroft P; McGuire S; Crossman AR; Menniti FS; Brotchie JM
    Exp Neurol; 2004 Aug; 188(2):471-9. PubMed ID: 15246846
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The hypothesis of the genesis of motor complications and continuous dopaminergic stimulation in the treatment of Parkinson's disease.
    Stocchi F
    Parkinsonism Relat Disord; 2009 Jan; 15 Suppl 1():S9-S15. PubMed ID: 19131046
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differential effect of NR2A and NR2B subunit selective NMDA receptor antagonists on striato-pallidal neurons: relationship to motor response in the 6-hydroxydopamine model of parkinsonism.
    Fantin M; Auberson YP; Morari M
    J Neurochem; 2008 Jul; 106(2):957-68. PubMed ID: 18435828
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recognition and treatment of response fluctuations in Parkinson's disease: review article.
    Verhagen Metman L
    Amino Acids; 2002; 23(1-3):141-5. PubMed ID: 12373528
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Action mechanism of L-dopa: dopaminergic activation or glutamatergic inhibition?].
    Vamvakidès A
    Ann Pharm Fr; 1993; 51(1):8-15. PubMed ID: 8215122
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Striatal synaptic changes in experimental parkinsonism: role of NMDA receptor trafficking in PSD.
    Picconi B; Ghiglieri V; Bagetta V; Barone I; Sgobio C; Calabresi P
    Parkinsonism Relat Disord; 2008; 14 Suppl 2():S145-9. PubMed ID: 18583173
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.